Liminatus Pharma, Inc. Class A Common Stock
LIMN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.34M
Close$
$-2.33
182.5% downside
Current Fair Value
182.5% downsideOvervalued by 182.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.34 Million |
|---|---|
| Enterprise Value | $-234,896.00 |
| Earnings per Share | $-21.5 |
| Beta | 0.75 |
| Outstanding Shares | 475,071 |
Return
| Return on Equity | -4165.92% |
|---|---|
| Return on Assets | -367.93% |
| Return on Invested Capital | -3423.86% |
Valuation & Multiples
| P/E Ratio | -0.12 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -27.08 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 4.8 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.98%▼ 2.23% |
|---|---|
| Total Invested | $105,097▼ 58.58% |
| Investors Holding | 14▼ 1.00% |
About Liminatus Pharma, Inc. Warrants
4 employees
CEO: Chris Kim
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.